BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Current Cash

Track Freeline Therapeutics Holdings plc's current cash ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$29.45M
55.27% YoYΔ $-36.40M vs prior year quarter

Peer trimmed avg / median

Loading

Freeline Therapeutics Holdings plc Current Cash History

Loading

Freeline Therapeutics Holdings plc vs. peers: Current Cash Comparison

Loading

Freeline Therapeutics Holdings plc Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc posts a current cash of $29M as of September 2023. That compares with $66M in the prior-year period — down 55.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Freeline Therapeutics Holdings plc's current cash was $66M. The latest reading is $29M — a 55.3% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Freeline Therapeutics Holdings plc's financial statement story. At $29M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for FRLN's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Freeline Therapeutics Holdings plc's other metric pages and overview cover the third.

Judging Freeline Therapeutics Holdings plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $29M here, then scan peer and history charts to see if the gap is persistent.